UNSPSC 51172329: Trientine dihydrochloride

This classification denotes a metal chelator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC3NX54582. European Medicines Agency schedules Trientine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04953MIG. Trientine dihydrochloride generally arises in the molecular formula C6H18N4.2CLH. The term TRIENTINE DIHYDROCHLORIDE is a United States Adopted Name designation. Most nations schedule trientine dihydrochloride under HS 29212900 and SITC 51452. SMILES: CL.CL.N(CCNCCN)CCN.

UNSPSC 51172329 Trientine dihydrochloride is a Commodity code that nominally covers a specific pharmaceutical chelating agent, but recent state and local procurement activity under this code does not align with trientine dihydrochloride purchasing. Instead, the opportunities tagged to this code encompass offender drug testing services, therapeutic pharmacy initiatives, and generic multi-source pharmaceutical and OTC product supply agreements. The scope of work actually being solicited includes specimen collection and laboratory drug screening with immunoassay and confirmatory testing (LC/MS/MS, GC/MS), operation of randomized testing notification systems, direct-to-manufacturer prescription fulfillment models, and aggregated generic pharmaceutical distribution across state and local health and correctional facilities. Issuing bodies include county corrections and community supervision departments, state health and human services agencies, and multistate cooperative purchasing alliances administering on behalf of multiple participating state and local jurisdictions.

Geographic activity centers on Texas, where Collin County Community Supervision and Corrections Department posted an RFP for offender specimen collection and drug testing services (RFP 2026-327, due July 23, 2026, estimated contract value $600,000, two-year term with three optional one-year renewals) requiring lab certification from SAMHSA, TX DPS, or CAP and approximately 25,031 annual tests across five- and six-panel screens with oral fluid and hair testing capabilities. The Texas Health and Human Services Commission issued a Request for Information in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, an exploratory phase preceding formal competitive procurement. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), solicited multiple contracts for generic multi-source pharmaceuticals and OTC products (RFP S1070000015802, proposals due March 26, 2026, serving state and local facilities in Minnesota, Oregon, and other participating jurisdictions) with price competitiveness weighted at 75 percent and contract terms of two years for new vendors with optional extensions through June 30, 2028. The code shows little direct activity in trientine dihydrochloride procurement and appears to be misaligned with its nominal scope across recent state and local opportunities.